Nurix Therapeutics
IPONurix | Medicines to Outmatch Disease
Public · San Francisco, United States · $162.0M raised
- Headquarters
- San Francisco, California
- Employees
- 51–200
- Business Model
- B2B
- Website
- nurixtx.com
- Total Funding
- $162.0M
- Last Round
- $102.0M Series CJan 2019
- Rounds
- 2
- Type
- Public
About
Nurix Therapeutics is a clinical-stage biotech pioneering targeted protein degradation using its DEL-AI platform to develop next-generation medicines for cancer and other diseases.
Summary
Nurix Therapeutics is a Biotech company based in San Francisco, United States. It has raised $162.0M in total across 2 rounds, most recently a $102.0M Series C round in Jan 2019. Investors include Deerfield Management.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Aug 2020
Sign up to see all 3 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...